About GEn1E
GEn1E is a company based in Palo Alto (United States) founded in 2018 by Ritu Lal.. GEn1E has raised $22.67 million across 4 funding rounds from investors including Clear Ventures and Y Combinator. GEn1E offers products and services including GEn-1124, p38α:MK2 Dual Signal Modulators, and NextGen ERK 1/2 Modulators. GEn1E operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Mereo BioPharma and Nimbus Therapeutics, among others.
- Headquarter Palo Alto, United States
- Founders Ritu Lal
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$22.67 M (USD)
in 4 rounds
-
Latest Funding Round
$5.52 M (USD), Series A
Oct 21, 2025
-
Investors
Clear Ventures
& 1 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of GEn1E
GEn1E offers a comprehensive portfolio of products and services, including GEn-1124, p38α:MK2 Dual Signal Modulators, and NextGen ERK 1/2 Modulators. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Dual signal modulator for treating ARDS and inflammation.
Chronic oral treatment for inflammatory diseases.
Modulators targeting kinase dysregulation in diseases.
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of GEn1E
GEn1E has successfully raised a total of $22.67M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $5.52 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series A — $5.5M
-
First Round
First Round
(21 Aug 2019)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2025 | Amount | Series A - GEn1E | Valuation |
investors |
|
| Dec, 2022 | Amount | Series A - GEn1E | Valuation |
investors |
|
| Jun, 2021 | Amount | Seed - GEn1E | Valuation | Clear Ventures |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in GEn1E
GEn1E has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Clear Ventures and Y Combinator. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Tech focused early stage VC firm investing in the US, Europe, Asia
|
Founded Year | Domain | Location | |
|
Early-stage startups are accelerated via funding and educational programs.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by GEn1E
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - GEn1E
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Gen1e Comparisons
Competitors of GEn1E
GEn1E operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Mereo BioPharma and Nimbus Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for inflammatory diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Gen1e
Frequently Asked Questions about GEn1E
When was GEn1E founded?
GEn1E was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Where is GEn1E located?
GEn1E is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Who is the current CEO of GEn1E?
Ritu Lal is the current CEO of GEn1E. They have also founded this company.
Is GEn1E a funded company?
GEn1E is a funded company, having raised a total of $22.67M across 4 funding rounds to date.
What does GEn1E do?
Founded in 2018 and based in Palo Alto, United States, therapeutics for inflammatory and rare diseases are developed through an AI-driven platform. Multiple mechanisms of action in protein targets are addressed to advance novel therapies. The lead candidate, GEn-1124, targets chronic lung conditions, while other molecules remain in research and discovery phases within the biotechnology sector.
Who are the top competitors of GEn1E?
GEn1E's top competitors include Moderna, Spark Therapeutics and BridgeBio.
What products or services does GEn1E offer?
GEn1E offers GEn-1124, p38α:MK2 Dual Signal Modulators, and NextGen ERK 1/2 Modulators.
Who are GEn1E's investors?
GEn1E has 2 investors. Key investors include Clear Ventures, and Y Combinator.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.